The Utility of Lens Culinaris Agglutinin-reactive Alpha-fetoprotein in the Diagnosis of Hepatocellular Carcinoma: Evaluation in a United States Referral Population
Overview
Authors
Affiliations
Background & Aims: The percentage of Lens culinaris agglutinin-reactive (alpha)-fetoprotein (AFP-L3%) is proposed as a diagnostic and prognostic marker for hepatocellular carcinoma (HCC). We evaluated the utility of AFP-L3% for diagnosis of HCC in a US referral population.
Methods: This retrospective study included 272 patients: 166 with HCC and 106 with benign liver disease (chronic liver disease, 77; benign liver mass, 29). The AFP-L3% was measured using a clinical auto-analyzer.
Results: The AFP-L3% is not reported for a total alpha-fetoprotein (AFP) less than 10 ng/mL, and all patients with an AFP greater than 200 ng/mL had HCC; thus the AFP-L3% was noninformative for these patients. In patients with a total AFP of 10-200 ng/mL, an AFP-L3% greater than 10% had a sensitivity of 71% and a specificity of 63% for diagnosis of HCC. An AFP-L3% greater than 35% had a reduced sensitivity of 33%, but an increased specificity of 100%. The high specificity of the AFP-L3% cut-off of 35% allowed the confident diagnosis of an additional 10% of HCCs not diagnosed using an AFP cut-off of 200 ng/mL. After adjustment for AFP level, no association was observed between AFP-L3% and tumor size, stage, vascular invasion, grade, or survival.
Conclusions: Patients with indeterminate total AFP values of 10-200 ng/mL present a diagnostic dilemma. We found that an AFP-L3% greater than 35% has 100% specificity for HCC in these patients. AFP-L3%, used in combination with AFP, may be a clinically useful adjunct marker for the diagnosis of HCC.
Strategies for discovering novel hepatocellular carcinoma biomarkers.
Wu S, Zhu L, Feng X, Wang H, Li F World J Hepatol. 2025; 17(2):101201.
PMID: 40027561 PMC: 11866143. DOI: 10.4254/wjh.v17.i2.101201.
Marked elevation of serum alpha-fetoprotein following infection: A rare case report.
Lin Y, Zong X, Li M, Wan S, Yu H, Wei X Liver Res. 2025; 6(1):45-49.
PMID: 39959805 PMC: 11791854. DOI: 10.1016/j.livres.2022.03.001.
Current status and new directions for hepatocellular carcinoma diagnosis.
Tu J, Wang B, Wang X, Huo K, Hu W, Zhang R Liver Res. 2025; 8(4):218-236.
PMID: 39958920 PMC: 11771281. DOI: 10.1016/j.livres.2024.12.001.
Choi J, Thung S J Yeungnam Med Sci. 2024; 42:5.
PMID: 39442859 PMC: 11812079. DOI: 10.12701/jyms.2024.00766.
Redefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies.
Yelsangikar A, Patil P J Clin Exp Hepatol. 2024; 14(6):101474.
PMID: 39108278 PMC: 11298640. DOI: 10.1016/j.jceh.2024.101474.